Mitoxantrone HCl
Mitoxantrone HCl (CAS 70476-82-3) is an antineoplastic small molecule inhibitor targeting DNA topoisomerase II (Topo-II). Topo-II enzymes manage DNA topology during replication and transcription, facilitating chromosome segregation and relieving torsional stress. Mitoxantrone interferes with Topo-II-mediated DNA cleavage and ligation, inducing double-strand DNA breaks and chromatin rearrangement, thus disrupting DNA synthesis and cell cycle progression. It modulates activity of immune cells including T cells, B cells, and macrophages. Research demonstrates mitoxantrone's apoptotic or senescence-inducing effects in normal human cell models. Its uses in biomedical research include studies on leukemia, multiple sclerosis, and pancreatic cancer cell viability.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 517.4 |
| Cas No. | 70476-82-3 |
| Formula | C22H29ClN4O6·HCl |
| Solubility | insoluble in EtOH; ≥51.53 mg/mL in DMSO; ≥2.97 mg/mL in H2O with ultrasonic |
| Chemical Name | 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione;dihydrochloride |
| SDF | Download SDF |
| Canonical SMILES | C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
DPSCs and HDFs |
|
Preparation method |
The solubility of this compound in DMSO is > 18.2 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
5, 20, 50, 100 and 150 nM |
|
Applications |
Mitoxantrone HCl almost completely inhibited DPSCs and HDFs proliferation without causing significant decrease in cell viability after 6 days. Mitoxantrone HCl, at higher doses, i.e. 100 nM and 150 nM, significantly decreased DPSCs and HDFs viability after 3 days. In addition, Mitoxantrone HCl at doses over 50 nM significantly increased the activity of caspases 3/7 and the level of puma, inducing DPSCs and HDFs apoptosis. |
| Animal experiment [2]: | |
|
Animal models |
Mice bearing PAC120 and HID xenografts |
|
Dosage form |
1 mg/kg; i.p.; once per 3 weeks |
|
Applications |
In mice bearing PAC120 xenografts, Mitoxantrone HCl was well tolerated, although it caused a weight loss of 10% or less. However, it did not inhibit tumor growth. In mice bearing HID xenografts, Mitoxantrone HCl transiently inhibited tumor growth with the optimal effect 3 weeks after the start of treatment. After 30 days, Mitoxantrone HCl no longer exhibited any inhibitory effect on tumor growth. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Seifrtova M, Havelek R, Soukup T, Filipova A, Mokry J, Rezacova M. Mitoxantrone ability to induce premature senescence in human dental pulp stem cells and human dermal fibroblasts. J Physiol Pharmacol. 2013 Apr;64(2):255-66. [2]. Oudard S, Legrier ME, Boyé K, Bras-Gonalves R, De Pinieux G, De Cremoux P, Poupon MF. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
